Cagrilintide
Also known as long-acting amylin analog, AM833
Cagrilintide is a long-acting amylin analog studied as a research compound — a different receptor family from the incretin agonists it is often paired with. Its research-use profile and handling.
Cagrilintide is easy to miscategorize, because it is almost always mentioned in the same breath as the GLP-1 agonists — yet structurally it is not one of them. It is an analog of amylin, a peptide the pancreas co-secretes alongside insulin, and it acts through a completely different receptor family. That difference is exactly why researchers find it interesting to study next to incretins rather than as another version of them.
As with the incretin analogs in this cluster, cagrilintide is described here with deliberate restraint: molecular class and design only, framed as a research compound under research-use-only conditions. No therapeutic, metabolic-outcome, dosing, or efficacy claims are made.
A synthetic analog of amylin — the pancreatic peptide co-secreted with insulin — rather than an incretin. It is acylated for extended circulation, but its receptor family is entirely different from the GLP-1 class: amylin analogs act at amylin/calcitonin-family receptors. That distinction is the whole point of studying it. Described strictly as a research compound.
Amylin, not incretin
Amylin (also called islet amyloid polypeptide) is a peptide hormone released together with insulin. Cagrilintide is a long-acting synthetic analog of it — an agonist at amylin/calcitonin-family receptors, which are distinct from the GIP and GLP-1 receptors that the incretin agonists target.
So while cagrilintide sits in the same broad 'metabolic research peptide' shelf as semaglutide and tirzepatide, it belongs to a different structural and receptor lineage. Keeping that straight is the single most useful thing to know about it.
Why it's studied alongside GLP-1 agonists
Cagrilintide appears frequently in the literature paired with GLP-1 agonists — the two are studied together precisely because they act through different receptor systems. Combining or comparing an amylin analog with an incretin agonist is a way researchers probe how distinct metabolic-signaling pathways relate. That pairing is a research-design choice; it says nothing about outcomes and implies no use.
This is a close parallel to how BPC-157 and TB-500 are discussed together despite being unrelated molecules: overlap in research context, not in structure.
The acylation it shares with the incretins
One thing cagrilintide does share with the long-acting incretin analogs is the acylation strategy — a fatty-acid chain that supports albumin binding and a longer circulation time. That is a common peptide-engineering technique across families; it explains the 'long-acting' descriptor without changing the fact that its receptor target is amylin's, not GLP-1's.
These are research areas the compound is associated with in the literature — not medical claims or intended uses.
Handling & storage
Supplied lyophilized. Kept sealed and cold, reconstituted only when a research protocol requires it and then refrigerated. Handled per accepted laboratory practice for acylated peptide analogs. Research use only.
Verify a certificate by lot →Common questions
No. It is a long-acting amylin analog and acts through the amylin/calcitonin receptor family — a different system from the GLP-1 and GIP receptors. It is often discussed alongside GLP-1 agonists but is not one.
A peptide hormone the pancreas co-secretes with insulin. Cagrilintide is a synthetic, long-acting analog of it. This is a descriptive statement of class, not of use.
Because they act through different receptor pathways, so studying them together lets researchers examine how distinct metabolic-signaling systems relate. That is a research-design rationale only.
This monograph is a research-use reference. It describes composition and the contexts in which the compound has been studied — it is not medical advice, a description of effects, or a recommendation for use. Sold strictly for laboratory and research use; not for human or animal consumption.